Jupiter Life Line Hospitals Ltd

Financial Performance

• Total income for Q1 FY27 stood at INR 411 crores.
• EBITDA was INR 79.3 crores with a 19.3% margin.
• PAT stood at INR 37.5 crores.
• ARPOB for the quarter was INR 73,500; ALOS 3.76 days.
• Occupancy was 59.6% this quarter, including expanded Dombivli beds.
• Dombivli completed its first full quarter with EBITDA drag of INR 9.5 crores.
• Three other operating hospitals and three upcoming projects are on track.

Operating Update

• Indore revenue grew about 10% YoY; higher HR costs due to expansion.
• Indore occupancy around 50%.
• Thane occupancy around mid-70%; Pune around mid-60%.
• Dombivli occupancy currently 25-30%.
• Fixed costs at Dombivli around INR 6-7 crores per month.
• Doctor hiring at Dombivli continues; ramp to add subspecialties.

Balance Sheet and Cash Flow

• Net debt is near zero; debt around INR 500 crores and cash around INR 500 crores.
• Board ceiling is 3x EBITDA; current capex to be funded within that range.
• Internal accruals expected to fund the next capex cycle.
• Pledge clarification: not promoter; corrected misreport due to split.

Projects and Capex

• Three existing hospitals and three upcoming projects are on track.
• IV fluids unit acquisition cost around INR 35-40 crores.
• Backward integration of pharmacy unit to improve margins.

Outlook and Guidance

• Dombivli EBITDA drag guidance: INR 2-3 crores per month.
• No aggressive revision yet; will update after 1-2 quarters.
• Inflation-linked growth expected for mature units; Indore occupancy to improve.

Q&A Highlights

• Unbilled revenue was a one-time policy change; future impact minimal.
• Dombivli occupancy currently 25-30%; empanelment should raise occupancy.
• Breakeven guidance for Dombivli remains; not aggressively revised yet.
• Location rationale: BKC premium area; accessible to many Mumbai residents.

Materiality authority and disclosure

• Board authorized MD & CEO Dr. Ankit Thakker and CFO Harshad Purani to determine materiality.
• The same officers are empowered to decide materiality of events for disclosure.
• Company Secretary and Compliance Officer Suma Upparatti is authorized for disclosures.
• Authority granted at board meeting held on 31 July 2026.
• Regulation reference: Regulation 30(5) of SEBI Listing Regulations 2015.
• Disclosure will be made to stock exchanges and posted on the company website.

Business Overview

• Core business: private multi-specialty hospitals; expanding at Dombivli, Pune II, Mira-Bhayandar, BKC.
• Strategy focuses on scaling bed capacity via phased commissioning.
• Insurance empanelment initiated to boost patient inflows.

Operational Highlights

• Q1FY27: Dombivli full-quarter operations with 200 beds; ramp-up loss ₹9.5 Cr.
• Bed capacity expansion plan: 500 Dombivli, 500 Pune II, 300 Mira-Bhayandar, 400 BKC.
• Total bed count target rising to 2,900 from 1,700.

Financial Performance

• Revenue from operations ₹392.6 Cr; total income ₹411.0 Cr in Q1FY27.
• YoY revenue growth: 16.2%; QoQ growth: 5.6%.
• EBITDA ₹79.3 Cr; EBITDA margin 19.3%.
• PBT ₹50.6 Cr; PAT ₹37.5 Cr; PBT margin 12.3%; PAT margin 9.1%.
• Depreciation increased due to capitalised beds; finance costs higher due to expansion debt.
• Internal cash flow to EBITDA conversion ~75-80% over five years.

Capital Structure & Liquidity

• Funding philosophy: internal accruals to fund expansion capex.
• Finance costs rose with debt for expansion.

Strategic Priorities & Outlook

• Phased commissioning to optimize capital deployment.
• Strategic land bank in high-demand micro markets.
• Scale bed capacity toward 2,900 beds to drive operating leverage.

Risks & Mitigation

• Ramp-up delays and higher marketing costs during launch.
• Debt-related financing risk mitigated by phased capex and internal accruals.

Governance & Leadership

• MD & CEO Dr. Ankit Thakker highlighted ramp-up progress.
• No governance changes disclosed.

Acquisition of Sulcus Private Limited

• Target: Sulcus Private Limited, in IV fluids, infusions and pharmaceutical manufacturing in India.
• Size/scale: NIL turnover; 10,000 equity shares; cash price ₹3.78 crore.
• Related party: Promoter group comprising Dr Ankit Thakker and Mrs K Thakker; arm's length, independent valuation.
• Industry: Pharmaceuticals; impact: JHPPL to set up IV fluids and manufacturing facility near Ujjain.
• Approval: DMIC Vikram Udyogpuri Limited permission received.
• Timeline: SPA signed on July 31, 2026.
• Consideration: Cash; ₹3.78 crore.
• Shareholding: 100% of paid-up equity (10,000 shares) acquired.
• Background: Sulcus incorporated 23/08/2012; NIL turnover; land near Ujjain, MP, India.
• Rationale: Aligns with Jupiter Hospitals expansion; reduce costs; margins via new manufacturing facility.

Target company

• Target company: Jupiter Life Line Hospitals Limited.

Disclosing party

• Acquirer: Catalyst Trusteeship Limited (Debenture Trustee); not promoter group.

Transaction type

• Release of encumbrance on pledged shares.

Pre-transaction holding

• Encumbered shares: 33,51,950 (5.11%); voting rights: none.

Transaction details

• Released encumbrance on 1,67,59,750 shares; 5.11% of total; due to stock split; date July 25, 2026.

Post-transaction holding

• Encumbered shares after: 1,67,59,750 (5.11%); voting rights: none.

Date of transaction

• Date of transaction: July 25, 2026.

Share capital context

• Capital before/after: Rs 65,56,60,220; diluted capital not disclosed.

Pledge details

• Target company: Jupiter Life Line Hospitals Limited.
• Disclosing party: Catalyst Trusteeship Limited (Debenture Trustee); not promoter group.
• Transaction type: Creation of pledge over shares (encumbrance).
• Pre-holding: voting rights 0; encumbered shares 33,51,950 (5.11%).
• Pledged shares: 1,67,59,750 (25.56%); date: 25 June 2026; mode: creation of pledge.
• Post-holding: encumbered with acquirer 2,01,11,700 (30.67%).
• Date of transaction: June 25, 2026.
• Capital context: before/after Rs 13,11,32,044; 6,55,66,022 shares; diluted capital not disclosed.

Meeting Details

• Earnings conference call for Q1 FY27 on Aug 3, 2026, 10:00 IST; virtual, organised by Strategic Growth Advisors.
• Pre-registration required for the call.

Participants

• Key company participants: Managing Director & CEO and senior management team.

Purpose

• Discuss operational and financial performance for Q1 FY27.

Additional Notes

• Recording/presentation will be available on the company website.

Meeting Details

• Date and time: Monday, Aug 3, 2026, at 10:00 AM IST.
• Mode: virtual group earnings conference call.
• Event: Earnings Conference Call for Q1 FY27; organised by Jupiter Life Line Hospitals Ltd.
• Key participants: MD & CEO and Senior Management team.
• Purpose: discuss Q1 FY27 operational and financial performance.
• Availability: recording/presentation to be available on the company website.

Meeting Details

• Date: 31 July 2026.
• Time and location are not disclosed.

Key Agenda Items

• Consider, review and approve unaudited standalone and consolidated results for quarter ended June 30, 2026 (Limited Review Report).

Other Notes

• Trading window for Designated Persons and their Immediate Relatives remains closed till 48 hours after the results declaration.

AGM Details

• AGM held on July 17, 2026 at 11:00 IST via VC/OAVM.
• Record date: July 10, 2026; total record shareholders: 32,977.

Dividend

• Dividend: No dividend proposed or declared.

Key Resolutions

• Ordinary: Adoption of Audited Standalone Financial Statements for FY ended 31 March 2026.
• Ordinary: Adoption of Audited Consolidated Financial Statements for FY ended 31 March 2026.
• Ordinary: Appointment of Dr Ajay Thakker who retires by rotation.
• Special: Change in designation and remuneration of Dr Ajay Thakker as Chairman & Whole Time Director.
• Ordinary: Approval of subdivision of equity shares.
• Ordinary: Alteration of Capital Clause of Memorandum of Association.
• Special: Alteration of Articles of Association.
• Ordinary: Approval of material related party transaction with Jupiter Hospital Projects Private Limited.
• Ordinary: Ratification of remuneration payable to Cost Auditors for FY 2026–27.

Voting Results

• Item 1 passed; standalone statements adopted.
• Item 2 passed; consolidated statements adopted.
• Item 3 passed; Thakker re-appointed by rotation.
• Item 4 passed; Thakker designated Chairman & WTD.
• Item 5 passed; equity split approved; 42.82% of shares polled.
• Item 6 passed; MOA capital clause altered; 42.82% polled.
• Item 7 passed; Articles altered; 42.82% polled.
• Item 8 passed; RPT with Jupiter Hospital Projects approved.
• Item 9 passed; Cost Auditor remuneration ratified.

Director Changes

• Appointment of Dr Ajay Thakker as Chairman & Whole Time Director from 17 July 2026.
• Dr Ajay Thakker re-appointed as Director, retiring by rotation.

Auditor Arrangements

• Remuneration payable to Cost Auditors ratified for FY 2026–27.

Material Related Party Transactions

• Approval of related party transaction with Jupiter Hospital Projects Private Limited.